Luigi Nocera

Vita-Salute San Raffaele University, San Raffaele Hospital

Luigi Nocera, MD, was born in Mazzarino, Sicily, Italy. He obtained his medical degree at Università Vita-Salute San Raffaele in Milan with a dissertation topic on the metabolomic of prostate cancer, under the supervision of Prof. Montorsi and Prof. Briganti. During medical school, he completed a resarch fellowship at Vattikuti Urology Institute, Henry Ford Hospital, Detroit, under the supervision of Dr. Menon and Dr. Abdollah. Then, he started his residency at Università Vita-Salute San Raffaele and its affiliated Ospedale San Raffaele. Currenly, he is attending his PGY-4. During residency, he finalized a research fellowship at Centre de recherche du Centre hospitalier de l'Université de Montréal (CR-CHUM), Montreal, Canada, under the supervision of Prof. Karakiewicz. Moreover, he is currently attending a clinical fellowship at Onze Lieve Vrouw (OLV) Ziekenhuis, Aalst, Belgium and ORSI Academy, Melle, Belgium, under the supervision of Prof. Mottrie.
Dr. Nocera's main focuses are urologic oncology and minimally invasive surgery, with special interest in prostate cancer, urothelial cancer, kidney cancer and robotic surgery. He has been actively involved in research since medical school, publishing over 60 papers and 150 abstracts at national and international congresses. His H-index is 10 (Google Scholar), 8 (Scopus). He is reviewer for many oncological and urological high impacted journals including Journal of Urology, European Urology Oncology, Cancers, Journal of the National Comprehensive Cancer Network and Frontiers in Oncology. Moreover, he is currently member of European Urology Association and Società Italiana di Urologia.

Disclosure information not submitted.

Presentation(s):

• MP43-19: Drop-out Rates from Active Surveillance for Disease Progression Remain Consistent and Not Negligible Over Time. A Plea for Long-term Assessment Based on a Large, Prospectively Collected Active Surveillance Cohort

  Sunday, May 15, 2022
  10:30 AM – 11:45 AM

• MP56-02: Neoadjuvant pembrolizumab may result in long-term outcome improvement in biomarker-unselected patients with muscle-invasive bladder cancer (MIBC): Updated results from PURE-01

  Monday, May 16, 2022
  10:30 AM – 11:45 AM

• MP56-04: The role of FDG PET in the staging of bladder cancer patients candidate for radical cystectomy

  Monday, May 16, 2022
  10:30 AM – 11:45 AM